| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bbdc68ca0aa38fef2d059853ef2b31e6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2330-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-141
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2330-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-711
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6869
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-243 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-711
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6869
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate |
2020-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3794d9f7257ed0e41fd4d4b473e35a6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05d6396041d6fc753812465f2d5ff95f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae1741f795af70c5ca3591eb0ad3d998 |
| publicationDate |
2020-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020299777-A1 |
| titleOfInvention |
Methods for Resensitizing p53-Null Cells to Cancer Chemotherapy |
| abstract |
The present disclosure is directed to methods for treating patients who have been diagnosed with cancers having a TP53 mutation. Aspects of the disclosure can be implemented to determine a treatment course for patients who have been diagnosed with a cancer having a TP53 mutation by excluding pharmaceutical compounds based, at least in part, on a genetic profile of the cancer. Additionally, aspects of the disclosure can be implemented to mitigate the effects of TP53 mutations by targeting biological pathways such as the spindle assembly checkpoint (SAC) to enhance or otherwise improve the efficacy of certain FDA-approved compounds. For instance, an example implementation of the disclosure can include a method for treating a patient who has been diagnosed with a cancer having a TP53 mutation. Advantages of the embodiments disclosed herein can provide patients with improved treatment efficacy when using chemotherapies or by reducing exposure to chemotherapeutics that demonstrate lower efficacy based on the genetic profile of the cancer. |
| priorityDate |
2019-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |